NASDAQ: ICCCImmucell Revenue
Immucell revenue was $27.77M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $5.5M, down 14.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ICCC annual revenue was $26.5M, with 51.6% growth year-over-year.
ICCC past revenue growth
How has ICCC's revenue growth performed historically?
Company
16.49%
Industry
294.99%
Market
20.47%
ICCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ICCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ICCC's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
ICCC revenue history
Current Revenue
$27.8M
Current Earnings
$2.3M
Current Profit Margin
8.4%
ICCC's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when ICCC announces revenue.
ICCC Revenue History By Year
| ICCC Yearly Revenue | ICCC Revenue | ICCC Change | ICCC Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $26.49M | $9.02M | +51.64% |
| 2023-12-31 | $17.47M | -$1.10M | -5.90% |
| 2022-12-31 | $18.57M | -$675.01k | -3.51% |
| 2021-12-31 | $19.24M | $3.90M | +25.43% |
| 2020-12-31 | $15.34M | $1.62M | +11.80% |
| 2019-12-31 | $13.72M | $2.74M | +24.91% |
| 2018-12-31 | $10.99M | $555.21k | +5.32% |
| 2017-12-31 | $10.43M | $887.13k | +9.30% |
| 2016-12-31 | $9.54M | -$684.73k | -6.69% |
| 2015-12-31 | $10.23M | $2.63M | +34.64% |
| 2014-12-31 | $7.60M | $1.59M | +26.46% |
| 2013-12-31 | $6.01M | $617.24k | +11.45% |
| 2012-12-31 | $5.39M | $278.79k | +5.45% |
| 2011-12-31 | $5.11M | $724.95k | +16.53% |
| 2010-12-31 | $4.39M | -$119.56k | -2.65% |
| 2009-12-31 | $4.51M | -$122.55k | -2.65% |
| 2008-12-31 | $4.63M | -$1.44M | -23.74% |
| 2007-12-31 | $6.07M | $1.27M | +26.41% |
| 2006-12-31 | $4.80M | -$181.87k | -3.65% |
| 2005-12-31 | $4.98M | $1.29M | +34.82% |
| 2004-12-31 | $3.70M | $338.94k | +10.10% |
| 2003-12-31 | $3.36M | -$2.83M | -45.72% |
| 2002-12-31 | $6.18M | -$492.06k | -7.37% |
| 2001-12-31 | $6.68M | $1.04M | +18.47% |
| 2000-12-31 | $5.64M | $726.74k | +14.80% |
| 1999-12-31 | $4.91M | $427.38k | +9.54% |
| 1998-12-31 | $4.48M | -$74.81k | -1.64% |
| 1997-12-31 | $4.56M | $116.49k | +2.62% |
| 1996-12-31 | $4.44M | -$497.34k | -10.07% |
| 1995-12-31 | $4.94M | $498.78k | +11.24% |
| 1994-12-31 | $4.44M | $497.41k | +12.62% |
| 1993-12-31 | $3.94M | N/A | N/A |
Immucell Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.